Skip to main content

Market Overview

Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder

  • Following consultations with FDA and European Medical Agency, Opthea NASDAQ: OPT) has finalized trial designs for two Phase 3 clinical trials to assess 2 mg OPT-302, administered 4-weekly or 8-weekly in wet age-related macular degeneration (AMD).
  • Each trial will enroll around 990 treatment-naive patients and assess the efficacy and safety of intravitreal 2.0 mg OPT-302 in combination with 0.5 mg Roche's Lucentis (ranibizumab) (ShORe trial) or 2.0 mg Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) (COAST trial), compared to ranibizumab or aflibercept monotherapy, respectively.
  • The primary endpoint for both trials is the mean change in Best Corrected Visual Acuity from baseline to week 52 for OPT-302 combination therapy compared to monotherapy.
  • Each patient will continue to be treated for a further year to evaluate extended safety and tolerability over two years.
  • The trials will start in the first quarter of 2021, with topline data expected in the second half of 2023.
  • Price Action: OPT closed 3.5% lower at $10.93 on Tuesday.

Related Articles (REGN + OPT)

View Comments and Join the Discussion!

Posted-In: Age-Related Macular DegenerationBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at